89 related articles for article (PubMed ID: 22687377)
1. Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition.
Rosendahl AH; Gundewar C; Said K; Karnevi E; Andersson R
Pancreatology; 2012; 12(3):219-26. PubMed ID: 22687377
[TBL] [Abstract][Full Text] [Related]
2. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Levitt RJ; Pollak M
Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282
[TBL] [Abstract][Full Text] [Related]
4. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Lev-Ari S; Zinger H; Kazanov D; Yona D; Ben-Yosef R; Starr A; Figer A; Arber N
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S276-80. PubMed ID: 16507392
[TBL] [Abstract][Full Text] [Related]
5. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
Hermanová M; Lukás Z; Nenutil R; Brázdil J; Kroupová I; Kren L; Pazourková M; Růzicka M; Díte P
Neoplasma; 2004; 51(2):77-83. PubMed ID: 15190415
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
7. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
8. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib toxicity is cell cycle phase specific.
Bock JM; Menon SG; Sinclair LL; Bedford NS; Goswami PC; Domann FE; Trask DK
Cancer Res; 2007 Apr; 67(8):3801-8. PubMed ID: 17440094
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Li J; Luo M; Wang Y; Shang B; Dong L
Oncol Rep; 2016 Sep; 36(3):1345-52. PubMed ID: 27430377
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
13. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
Winters ME; Mehta AI; Petricoin EF; Kohn EC; Liotta LA
Cancer Res; 2005 May; 65(9):3853-60. PubMed ID: 15867384
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Maier TJ; Schilling K; Schmidt R; Geisslinger G; Grösch S
Biochem Pharmacol; 2004 Apr; 67(8):1469-78. PubMed ID: 15041464
[TBL] [Abstract][Full Text] [Related]
18. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
19. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.
Schroeder CP; Kadara H; Lotan D; Woo JK; Lee HY; Hong WK; Lotan R
Cancer Res; 2006 Oct; 66(19):9762-70. PubMed ID: 17018636
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357.
Härdtner C; Multhoff G; Falk W; Radons J
Eur J Pharmacol; 2012 Jun; 684(1-3):36-43. PubMed ID: 22497997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
